HAVCR2 and neoplasm: TIM-3 blockade alone was demonstrated to have anti-solid tumor effects in preclinical studies by improving the ex vivo proliferation of tumor-infiltrating T cells and increasing the secretion of the cytokines IFN-γ and TNF-α (78, 79).